Here at the Janssen Health Policy Centre
our mission is to raise awareness on issues impacting healthcare policy, build
consensus through dialogue, and shape recommendations for future policies

High value, high uncertainty: Measuring risk in biopharmaceutical research and other industries.

Investing in the future of health

Europe’s biopharmaceutical industry faces highest business risks among six key industry sectors, according to a new comparative study. Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, the study concludes. The study was conducted by Deloitte and commissioned by Janssen. It compares six industry sectors: the biopharmaceutical industry, commercial aircraft manufacturing, the automotive industry, consumer electronics, food manufacturing and generic

Download the report here
Download the infographic (web)
Download the infographic (print)
Download the fact sheet
Download the pocket guide
Watch the video







Report archive